JOHN PHAIR MD
Prescription History 1033539705
Surgery - Vascular Surgery in Long Island City, NY

NPI Status: Active since April 22, 2014

Contact Information

25-20 30TH AVENUE
5TH FLOOR
LONG ISLAND CITY, NY
ZIP 11102
Phone: (718) 808-7777

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOHN PHAIR MD, an active Vascular Surgery specialist practicing in Long Island City, NY. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 168 documented patient claims. Among these therapy options, the most frequently utilized medication is Gabapentin, which accounts for 43 claims alone.

Medication Index


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: General Surgery
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 133
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.2
Peer Average Days Supply225
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.80

State Avg Cost Per Claim

$12.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cilostazol

Generic Formulation: CilostazolSpecialty: General Surgery
Provider Metrics Summary
Total Claims 13
30-Day Fills 31.0
Days Supply 930
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills44.4
Peer Average Days Supply1,309
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $387.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.79

State Avg Cost Per Claim

$23.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Therapeutic Applications

Cilostazol is used to improve the symptoms of a certain blood flow problem in the legs (intermittent claudication). Cilostazol can decrease the muscle pain/cramps that occur during exercise/walking. Claudication pain is caused by too little oxygen getting to the muscles. Cilostazol can increase blood flow and the amount of oxygen that gets to the muscles. Cilostazol is an antiplatelet drug and a vasodilator. It works by stopping blood cells called platelets from sticking together and prevents them from forming harmful clots. It also widens blood vessels in the legs. Cilostazol helps the blood to move more easily and keeps blood flowing smoothly in your body.

Clopidogrel

Generic Formulation: Clopidogrel BisulfateSpecialty: General Surgery
Provider Metrics Summary
Total Claims 33
30-Day Fills 91.0
Days Supply 2,730
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills117.0
Peer Average Days Supply3,448
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $601.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.24

State Avg Cost Per Claim

$15.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Therapeutic Applications

Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent). Clopidogrel works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.

Eliquis

Generic Formulation: ApixabanSpecialty: General Surgery
Provider Metrics Summary
Total Claims 20
30-Day Fills 23.0
Days Supply 638
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills127.9
Peer Average Days Supply3,554
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.4% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,396.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$619.81

State Avg Cost Per Claim

$816.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: General Surgery
Provider Metrics Summary
Total Claims 43
30-Day Fills 45.0
Days Supply 1,350
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills113.9
Peer Average Days Supply3,301
Conservative Utilization

This provider writes prescriptions for this formulation 44.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $434.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.10

State Avg Cost Per Claim

$17.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Santyl

Generic Formulation: Collagenase Clostridium Hist.Specialty: General Surgery
Provider Metrics Summary
Total Claims 18
30-Day Fills 25.4
Days Supply 761
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply521
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,315.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$961.97

State Avg Cost Per Claim

$586.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A metalloproteinase which degrades helical regions of native collagen to small fragments. Preferred cleavage is -Gly in the sequence -Pro-Xaa-Gly-Pro-. Six forms (or 2 classes) have been isolated from Clostridium histolyticum that are immunologically cross-reactive but possess different sequences and different specificities. Other variants have been isolated from Bacillus cereus, Empedobacter collagenolyticum, Pseudomonas marinoglutinosa, and species of Vibrio and Streptomyces. EC 3.4.24.3.

Therapeutic Applications

This medication is used to treat certain conditions (Dupuytren's contracture, Peyronie's disease) that are caused by a certain protein (collagen) in your body. Collagen is a tough and strong substance and is found in the knots/cords of the hand in Dupuytren's contracture or plaques in the penis in Peyronie's disease. Collagenase is a substance (enzyme) that breaks down the collagen in these knots/cords/plaques.

Xarelto

Generic Formulation: RivaroxabanSpecialty: General Surgery
Provider Metrics Summary
Total Claims 29
30-Day Fills 31.5
Days Supply 930
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills78.6
Peer Average Days Supply2,234
Conservative Utilization

This provider writes prescriptions for this formulation 34.1% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,811.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$545.21

State Avg Cost Per Claim

$894.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOHN PHAIR MD provides transparency into local medical care patterns within Long Island City, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Vascular Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.